TICKERNERD
Menu
NVNONVNOHealthcare · Medical Devices

NVNO Stock Forecast: enVVeno Medical Corp. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$8.18
−2.68% on the day

The 1 Wall Street analysts covering enVVeno Medical Corp. hold a median 12-month price target of $30 — +267.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.7M
Ticker Nerd rank
36 / 100
Median analyst target
$30
Analysts covering
1
Revenue$0.0
Operating income−$3.8M
Net income−$3.6M
Free cash flow−$3.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.7%
1M
−28.9%
YTD
−27.2%
1Y
−75.6%
From 52W high
−75.6%
From 52W low
+4.8%
$8
$33
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NVNO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores enVVeno Medical Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Growth
86
Accruals
67
Revisions
53
Issuance
50
Quality
22
Volatility
19
Momentum
6
Value
3

Size (95): Smaller than most of the companies we track.

Value (3): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NVNO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NVNO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30$35Jan 26Apr 26Jul 26Oct 26NVNOHigh $30Median $30Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $30Median $30High $30

The green dot is the last close — the median target sits +267.0% from it.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NVNO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NVNO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, enVVeno Medical Corp. returned −75.6% against +16.2% for the S&P 500, dividends included.

NVNO vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26NVNOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NVNO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

enVVeno Medical Corp. (NVNO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 79% of US stocks

Price / sales
—
Price / book
0.3×

Cheaper than 88% of US stocks

EV / EBITDA
0.9×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−58.5%

Higher than 20% of US stocks

Return on assets
−36.7%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

enVVeno Medical Corp. (NVNO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • enVVeno Medical Corp. has a market value of $5.7M and an enterprise value of −$15.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$15.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$14.6M.

  • Shares outstanding: 655,521.

  • Trailing P/E: −0.2×; forward P/E: −1.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • enVVeno Medical Corp. employs 33 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

NVNO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
NVNOenVVeno Medical Corp.$5.7M
36
VNRXVolitionRX Ltd.$6.1M
44
AMIXAutonomix Medical, Inc.$6.1M
10
INBSIntelligent Bio Solutions, Inc.$5.2M
15
VVOSVivos Therapeutics, Inc.$5.0M
28
WOKWORK Medical Technology Group Ltd.$6.8M
16
AIDX20/20 Biolabs, Inc.$4.6M
3

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own enVVeno Medical Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NVNO news & analysis

enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial

Accesswire · 2 Oct 2026positive

enVVeno Medical announced it will present its investigational enVVe System, a minimally invasive replacement venous valve being evaluated in a U.S. pivotal study, at The VEINS 2026 Innovation Summit in Las Vegas, Nevada. The presentation will be given by venous interventionalist Karen B. Garby, MD.

Why it matters — A presentation of the enVVe System at a major venous medicine summit highlights the company's progress toward its U.S. pivotal trial for a condition affecting an estimated 3 million patients with no effective treatment.

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand

Accesswire · 11 Sept 2026neutral

enVVeno Medical announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing. The announcement was made on September 11, 2026 and provides access to the video webcast.

Why it matters — The availability of the presentation allows NVNO investors and interested parties to review the company's latest updates and strategy shared at the H.C. Wainwright investment conference.

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference

Accesswire · 27 Aug 2026neutral

enVVeno Medical Corporation announced that CEO Robert Berman participated in the Virtual Investor "Why Now" on-demand conference. A video webcast of the event is now available.

Why it matters — NVNO watchers may care because the CEO's participation in an investor conference provides a readily accessible recorded presentation of the company's current position and strategy.

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments

Accesswire · 4 Aug 2026positive

enVVeno Medical announced the publication of a peer-reviewed health economic analysis in the Journal of Vascular Surgery: Venous and Lymphatic Disorders. The study found that its replacement venous valve therapy is economically dominant versus standard-of-care treatments for deep venous CVI, projecting over $32,000 in healthcare savings per patient over five years and fewer venous ulcers per patient. The company said the evidence will support future coverage determinations and reimbursement policies for its enVVe device.

Why it matters — NVNO watchers would care because the peer-reviewed economic data supporting reimbursement and coverage could strengthen the business case for enVVe adoption.

enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve

Accesswire · 31 July 2026positive

enVVeno Medical reported second quarter 2026 financial results and highlighted receiving FDA IDE approval to begin the TAVVE pivotal trial for its enVVe System, a non-surgical replacement venous valve for severe deep chronic venous insufficiency. Patient enrollment for the pivotal study is expected to start in the second half of 2026, with cash runway extending into the third quarter of 2027.

Why it matters — This marks the first-ever FDA IDE approval for a U.S. pivotal study of a transcatheter replacement venous valve, bringing enVVeno's enVVe System closer to potential commercialization for patients with severe deep CVI.

FAQ

Frequently asked questions about NVNO stock

What is the NVNO stock price forecast for 2026-2027?

The 1 Wall Street analysts covering enVVeno Medical Corp. have a median 12-month price target of $30, with estimates ranging from $30 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NVNO stock a buy right now?

Of the 1 analysts covering enVVeno Medical Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks enVVeno Medical Corp. 36 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NVNO?

As at 8 Oct 2026, enVVeno Medical Corp. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

Will NVNO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +267.0% from the last close, and Ticker Nerd's factor model ranks enVVeno Medical Corp. 36 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NVNO stock forecast for 2030?

No analyst covering enVVeno Medical Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NVNO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $30 over the next 12 months.

How has NVNO stock performed over the past year?

enVVeno Medical Corp. returned -75.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does enVVeno Medical Corp. do?

enVVeno Medical Corporation is a medical device company focused on developing bioprosthetic, tissue-based solutions for venous disease. The company’s current portfolio centers on the VenoValve, a surgical replacement venous valve designed for patients with deep venous chronic venous insufficiency, and enVVe, a non-surgical, transcatheter-based venous valve system under development.

What is the latest news on NVNO?

The most recent item we track (Accesswire, 2 Oct 2026): "enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial". enVVeno Medical announced it will present its investigational enVVe System, a minimally invasive replacement venous valve being evaluated in a U.S. pivotal study, at The VEINS 2026 Innovation Summit in Las Vegas, Nevada. The presentation will be given by venous interventionalist Karen B. Garby, MD.

Company

About enVVeno Medical Corp.

enVVeno Medical Corporation is a medical device company focused on developing bioprosthetic, tissue-based solutions for venous disease. The company’s current portfolio centers on the VenoValve, a surgical replacement venous valve designed for patients with deep venous chronic venous insufficiency, and enVVe, a non-surgical, transcatheter-based venous valve system under development. These products are intended to address valve failure in the deep venous system and support more effective blood flow in patients with chronic venous disorders. enVVeno Medical Corporation serves the broader vascular medicine market, where it aims to improve treatment options for conditions that can cause pain, swelling, and long-term circulatory problems. Based in Irvine, California and incorporated in 1999, the company remains a late clinical-stage player in specialized medical technology, with a business model centered on advancing implantable and minimally invasive venous care solutions.

CEO Mr. Robert A. Berman · 33 employees · United States · https://www.envveno.com